Please assess the completion status of the following clinical trial:

Trial Title: IGF-1, IGFBP3, ALS Normative Ranges in Healthy Pediatric Spanish Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children of either sex of Caucasian parents~* Age: newborns up to and including 18 years of age~* Length/height, weight and body mass index (BMI) within the mean +/- 2SD (Standard Deviation) and in accordance with the growth charts of the 2010 Spanish cross-sectional growth study (Carrascosa Lezcano et al 2010)~* Signed consent by at least one parent or legal guardian (if subject is ≤18 years) and by subject if ≥12 years~Exclusion Criteria:~* Early or advanced puberty (pubertal signs: between 8 and 9 years old in girls, and between 9 and 10 years old in boys), or delayed puberty (no puberty onset in ≥ 13 year-old girls, and in ≥ 14 year-old boys)~* Chronic diseases including, but not limited to, endocrinologic diseases, chromosomal diseases, chronic diseases of renal, hepatic and/or cardiac aetiology, and tumour processes~* An acute disease during the last two weeks prior to recruitment~* Any clinically significant out-of-range lab value~* Healthy paediatric volunteers who are under medical treatment (contraception permitted)~* A family history of short stature (either parent \< P3)~* Children born small for gestational age (birth weight, length, or head circumference \< P10)~* Adopted children or conceived through in vitro fertilization ( IVF )~* Subjects who are unwilling or unable in the opinion of the investigator or sponsor to undergo all the study procedures

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).